Med. praxi 2013; 10(8-9): 294-296

Current treatment of tobacco dependence

MUDr.Alexandra Kmeťová1, 2, doc.MUDr.Eva Králíková, CSc.1, 2
1 Ústav hygieny a epidemiologie, 1. lékařská fakulta a Všeobecná fakultní nemocnice, Univerzita Karlova v Praze
2 Centrum pro závislé na tabáku III. interní kliniky – kliniky endokrinologie a metabolizmu, 1. lékařská fakulta a Všeobecná fakultní nemocnice, Univerzita Karlova v Praze

Tobacco dependence is a chronic relapsing disease with psychosocial and physical component. Both characteristics of the disease require

treatment – psychosocial intervention and pharmacotherapy. The intensity of the treatment will vary according to the therapist time

possibilities from short interventions (within 5 minutes) up to intense and prolonged treatment. Currently we have 3 types of first-line

medications available – nicotine replacement therapy, which is available OTC in pharmacy and two drugs on prescription – varenicline

and bupropion. First contact physicians should pay attention to tobacco dependence, at least ask about smoking, recommend stopping

and offer brief intervention to each patient. If the smoker needs more intensive treatment that exceeds the available time of the clinician,

the patient may be reffered to any of Centers for Tobacco-Dependent from the current list available on SLZT.CZ.

Keywords: tobacco dependence, treatment, clinical practice, nicotine, bupropion, varenicline

Published: September 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kmeťová A, Králíková E. Current treatment of tobacco dependence. Med. praxi. 2013;10(8-9):294-296.
Download citation

References

  1. MKN-10, Mezinárodní statistická klasifikace nemocí a přidružených zdravotních problémů, 10. revize, druhé aktualizované vydání. Světová zdravotnická organizace. Praha: Ústav zdravotnických informací a statistiky ČR 2011. Dostupné z URL: http://www.uzis.cz/system/files/mkn-tabelarni-cast_1-1-2012.pdf.
  2. Sovinová H, Sadílek P, Csémy L. Vývoj prevalence kuřáctví v dospělé populaci ČR, názory a postoje občanů ČR k problematice kouření (období 1997-2009), výzkumná zpráva, SZU, 2010, dostupné na http://www.szu.cz/uploads/documents/czzp/zavislosti/koureni/Zprava2009DEF.pdf.
  3. Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed countries 1950-2000. Oxford, UK, Oxford University Press, 1994, update 2006, www.deathsfromsmoking.net.
  4. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER package. Geneva, World Health Organization, 2008.
  5. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire, Br J Addict., 1991; 86(9): 1119-1127. Go to original source... Go to PubMed...
  6. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nic Tob Res. 2012; 14(1): 75-78. Go to original source... Go to PubMed...
  7. McRobbie H, Bullen C, Glover M, Whittaker R, Wallace-Bell M, Fraser T. New Zealand Guidelines Group: New Zealand smoking cessation guidelines. N Z Med J. 2008; 121(1276): 57-70.
  8. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline, Rockville, MD, US Department of Health and Human Services, 2008.
  9. Králíková E, Býma S, Cífková R, Češka R, Dvořák V, Hamanová J, Horký K, Hradec J, Keller O, Konštacký S, Kos S, Kostřica R, Kunešová M, Kvapil M, Langrová K, Mayer O, Petrů V, Popov P, Raboch J, Rosolová H, Roztočil K, Sucharda P, Vorlíček J, Widimský J. Doporučení pro léčbu závislosti na tabáku, Časopis lékařů českých 2005; 144(5): 327-333. Go to PubMed...
  10. Zvolská K. Kardiovaskulární onemocnění a kouření [Cardiovascular disease and smoking]. Praha, 2013. 110 stran, 2 přílohy. Dizertační práce. Univerzita Karlova v Praze, 1. lékařská fakulta, III. Interní klinika. Školitel: Králíková, Eva.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.